宫颈癌预防性HPV疫苗应用现状及面临的挑战

doi:10.3760/cma.j.issn.1673-422X.2019.05.012

摘要/Abstract

摘要： 人乳头瘤病毒（HPV）疫苗2006年被美国食品和药物管理局批准用于女性癌症预防，目前共有3种类型的预防性HPV疫苗，其在发达国家的应用使HPV感染率、宫颈病变率都显著降低。发展中国家由于资金及宫颈癌知识的缺乏等原因导致HPV疫苗接种率较低。同时，对疫苗安全性的担忧使得发达国家的疫苗接种率有所降低。各国都面临着提高疫苗接种率的挑战。

关键词: 乳头状瘤病毒科, 宫颈肿瘤, 乳头状瘤病毒疫苗, 一级预防

Abstract: Human papillomavirus (HPV) vaccine is approved by the the U. S. Food and Drug Administration in 2006 for female cancer prevention. There are currently three types of prophylactic HPV vaccines, and its application in developed countries can significantly reduce HPV infection rates and cervical lesion rates. In developing countries, HPV vaccination rates are low due to lack of knowledge of cervical cancer and funds. At the same time, concerns about vaccine safety have led to a reduction in vaccination rates in developed countries. Countries are facing the challenge of increasing vaccination rates.

Key words: Papillomaviridae, Uterine cervical neoplasms, Papillomavirus vaccines, Primary prevention

李昂，魏芳. 宫颈癌预防性HPV疫苗应用现状及面临的挑战[J]. 国际肿瘤学杂志, 2019, 46(5): 307-310.

Li Ang, Wei Fang. Current status and future challenges of HPV preventive vaccine of cervical cancer[J]. Journal of International Oncology, 2019, 46(5): 307-310.

参考文献

［1］ Burk RD, Harari A, Chen Z. Human papillomavirus genome variants［J］. Virology, 2013, 445(1-2): 232-243. DOI: 10.1016/j.virol.2013.07.018. ［2］ Shen Y, Gong JM, Li YQ, et al. Epidemiology and genotype distribution of human papillomavirus (HPV) in women of Henan Province, China［J］. Clin Chim Acta, 2013, 415: 297-301. DOI: 10.1016/j.cca.2012.11.005. ［3］ Dela Cruz MRI, Tsark JAU, Chen JJ, et al. Human papillomavirus (HPV) vaccination motivators, barriers, and brochure preferences among parents in multicultural Hawai′i: a qualitative study［J］. J Cancer Educ, 2017, 32(3): 613-621. DOI: 10.1007/s13187-016-1009-2. ［4］ Kester LM, Zimet GD, Fortenberry JD, et al. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for nonvaccination［J］. Matern Child Health J, 2013, 17(5): 879-885. DOI: 10.1007/s10995-012-1066-z. ［5］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. ［6］ Garland SM, Kjaer SK, Muoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of realworld experience［J］. Clin Infect Dis, 2016, 63(4): 519-527. DOI: 10.1093/cid/ciw354. ［7］ Markowitz LE, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States［J］. Pediatrics, 2016, 137(3): e20151968. DOI: 10.1542/peds.2015-1968. ［8］ Saraiya M, Unger ER, Thompson TD, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines［J］. J Natl Cancer Inst, 2015, 107(6): djv086. DOI: 10.1093/jnci/djv086. ［9］ Fernandes R, Potter BK, Little J. Attitudes of undergraduate university women towards HPV vaccination: a cross-sectional study in Ottawa, Canada［J］. BMC Womens Health, 2018, 18(1): 134. DOI: 10.1186/s12905-018-0622-0. ［10］ Gilbert NL, Gilmour H, Dubé E, et al. Estimates and determinants of HPV non-vaccination and vaccine refusal in girls 12 to 14 y of age in Canada: results from the Childhood national immunization coverage survey, 2013［J］. Hum Vaccin Immunother, 2016, 12(6): 1484-1490. DOI: 10.1080/21645515.2016.1153207. ［11］ Machalek DA, Garland SM, Brotherton JML, et al. Very low prevalence of vaccine human papillomavirus types among 18to 35year old Australian women 9 years following implementation of vaccination［J］. J Infect Dis, 2018, 217(10): 1590-1600. DOI: 10.1093/infdis/jiy075. ［12］ Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study［J］. Lancet Public Health, 2019, 4(1): e19-e27. DOI: 10.1016/S24682667(18)30183X. ［13］ Qendri V, SchurinkVan′t Klooster TM, Bogaards JA, et al. Ten years of HPV vaccination in the Netherlands: current evidence and future challenges in HPVrelated disease prevention［J］. Expert Rev Vaccines, 2018, 17(12): 1093-1104. DOI: 10.1080/14760584.2018.1547196. ［14］ Mennini FS, Bonanni P, Bianic F, et al. Costeffectiveness analysis of the ninevalent HPV vaccine in Italy［J］. Cost Eff Resour Alloc, 2017, 15: 11. DOI: 10.1186/s12962-017-0073-8. ［15］ Largeron N, Petry KU, Jacob J, et al. An estimate of the public health impact and costeffectiveness of universal vaccination with a 9valent HPV vaccine in Germany［J］. Expert Rev Pharmacoecon Outcomes Res, 2017, 17(1): 85-98. DOI: 10.1080/14737167.2016.1208087. ［16］ Mesher D, Panwar K, Thomas SL, et al. Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing crosssectional study［J］. BMJ open, 2016, 6(2): e009915. DOI: 10.1136/bmjopen-2015-009915. ［17］ BaldurFelskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasianationwide follow-up of young Danish women［J］. J Natl Cancer Inst, 2014, 106(3): djt460. DOI: 10.1093/jnci/djt460. ［18］ Feiring B, Laake I, Christiansen IK, et al. Substantial decline in prevalence of vaccinetype and nonvaccinetype human papilloma-virus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in Norway［J］. J Infect Dis, 2018, 218(12): 19001910. DOI: 10.1093/infdis/jiy432. ［19］ Konno R, Konishi H, Sauvaget C, et al. Effectiveness of HPV vaccination against high grade cervical lesions in Japan［J］. Vaccine, 2018, 36(52): 7913-7915. DOI: 10.1016/j.vaccine.2018.05.048. ［20］ Kim MA, Han GH, Kim JH, et al. Current status of human papillomavirus infection and introduction of vaccination to the national immunization program in Korea: an overview［J］. J Korean Med Sci, 2018, 33(52): e331. DOI: 10.3346/jkms.2018.33.e331. ［21］ Zhu FC, Chen W, Hu YM, et al. Efficacy, immunogenicity and safety of the HPV16/18 AS04adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial［J］. Int J Cancer, 2014, 135(11): 2612-2622. DOI: 10.1002/ijc.28897. ［22］ Wei L, Xie X, Liu J, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebocontrolled trial with 78-month follow-up［J］. Vaccine, 2018, pii: S0264-410X(18)31116-2. DOI: 10.1016/j.vaccine.2018.08.009. ［23］ Buang SN, Ja'afar S, Pathmanathan I, et al. Human papillomavirus immunisation of adolescent girls: improving coverage through multisectoral collaboration in Malaysia［J］. BMJ, 2018, 363: k4602. DOI: 10.1136/bmj.k4602. ［24］ Garon J, Wuddhika IV, Sreenivasan N, et al. Communitybased household assessment of human papillomavirus (HPV) vaccination coverage and acceptabilityHPV vaccine demonstration program, Cambodia2017［J］. Vaccine, 2019, 37(9): 1202-1208. DOI: 10.1016/j.vaccine.2018.12.052. ［25］ Bruni L, Diaz M, BarrionuevoRosas L, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis［J］. Lancet Glob Health, 2016, 4(7): e453e463. DOI: 10.1016/S2214-109X(16)30099-7. ［26］ Owsianka B, Gańczak M. Evaluation of human papilloma virus (HPV) vaccination strategies and vaccination coverage in adolescent girls worldwide［J］. Przegl Epidemiol, 2015, 69(1): 53-58, 151-155. ［27］ Kalinowski P, Grzdziel A. HPV vaccinations in Lublin region, Poland［J］. Postepy Hig Med Dosw (Online), 2017, 71(0): 92-97. ［28］ Latsuzbaia A, Arbyn M, Weyers S, et al. Human papillomavirus vaccination coverage in Luxembourgimplications of lowering and restricting target age groups［J］. Vaccine, 2018, 36(18): 2411-2416. DOI: 10.1016/j.vaccine.2018.03.054. ［29］ Klinsupa W, Pensuk P, Thongluan J, et al. O16.3 Hpv vaccine introduction in Thailand［J］. Sex Transm Infect, 2015, 91 Suppl 2: A61. DOI: org/10.1136/sextrans-2015-052270.167. ［30］ Perez S, Zimet GD, Tatar O, et al. Human papillomavirus vaccines: successes and future challenges［J］. Drugs, 2018, 78(14): 1385-1396. DOI: 10.1007/s40265-018-0975-6. ［31］ Hanley SJ, Yoshioka E, Ito Y, et al. HPV vaccination crisis in Japan［J］. Lancet, 2015, 385(9987): 2571. DOI: 10.1016/S0140-6736(15)61152-7. ［32］ Juntasopeepun P, Thana K. Parental acceptance of HPV vaccines in Chiang Mai, Thailand［J］. Int J Gynaecol Obstet, 2018, 142(3): 343-348. DOI: 10.1002/ijgo.12539.

[1]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.
[2]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[3]	吕璐, 孙鹏飞. 肠道菌群与宫颈癌[J]. 国际肿瘤学杂志, 2023, 50(6): 373-376.
[4]	段传菊, 陈真云, 李晓红, 牛洪朋, 李秀敏. 复发宫颈癌免疫治疗1例[J]. 国际肿瘤学杂志, 2023, 50(12): 766-768.
[5]	马雪艳, 鲁历历, 孙鹏飞. 免疫微环境在宫颈癌中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(1): 47-50.
[6]	张露, 周菊英, 马辰莺, 林州. 复发转移性宫颈癌免疫治疗相关进展[J]. 国际肿瘤学杂志, 2022, 49(9): 517-520.
[7]	史英侠, 胡莉钧, 于静萍. 免疫检查点抑制剂在复发或转移性宫颈癌治疗中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 568-571.
[8]	彭琛, 谢印通, 张昕, 谢鹏. 宫颈癌维持治疗研究进展[J]. 国际肿瘤学杂志, 2022, 49(7): 430-435.
[9]	熊婵, 阎英, 谢晓冬, 孟繁杰, 于卉影. 辐射诱导的多倍体宫颈癌HeLa细胞生物学特性研究[J]. 国际肿瘤学杂志, 2022, 49(5): 263-269.
[10]	袁晨阳, 周菊英. 宫颈癌预后因素的研究进展[J]. 国际肿瘤学杂志, 2022, 49(5): 307-313.
[11]	袁晨阳, 周菊英, 杜霄, 纪环, 赵天翼. 宫颈癌2018与2009 FIGO分期的比较及预后因素分析[J]. 国际肿瘤学杂志, 2022, 49(3): 151-163.
[12]	王玥, 吴琼, 许愿, 龚唯, 徐晓婷. 老年宫颈癌的筛查与治疗进展[J]. 国际肿瘤学杂志, 2022, 49(12): 754-758.
[13]	马秀珍, 卢艳, 赵冰冰, 邱宏聪, 徐勋, 韦敏. 岗松总黄酮对宫颈癌SiHa细胞迁移、侵袭及凋亡的影响[J]. 国际肿瘤学杂志, 2021, 48(4): 206-211.
[14]	牛雯娟, 段文杰, 苏雅婷, 魏芳. 对2018年国际妇产联盟宫颈癌新分期的思考[J]. 国际肿瘤学杂志, 2021, 48(10): 627-630.
[15]	于明月, 陈峥峥, 赵旭旭, 任萍萍, 张影, 葛丽, 朱美玲, 赵卫东. 局部晚期宫颈癌术后辅助治疗的影响因素及其列线图风险模型的构建[J]. 国际肿瘤学杂志, 2021, 48(1): 35-40.